Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,618 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Retinal Disease Clear all
Completed Phase 4 Interventional

NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions

NCT01870427
View directory record Official record
Conditions
Macular Edema With Central Retinal Vein Occlusions
Interventions
Aflibercept (2.0 mg)
Drug
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 24, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations

NCT00481546
View directory record Official record
Conditions
Amaurosis of Leber, Retinal Diseases
Interventions
rAAV2-CBSB-hRPE65
Genetic
Lead sponsor
University of Pennsylvania
Other
Eligibility
8 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 24, 2026, 2:34 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results

NCT01657669
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Intravitreal Aflibercept injection
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
50 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
3
States / cities
St Louis, Missouri • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 24, 2026, 2:34 PM EDT
Active, not recruiting No phase listed Observational

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

NCT05797896
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration, Macular Atrophy, Retinal Degeneration, Eye Diseases
Interventions
Not listed
Lead sponsor
Complement Therapeutics
Industry
Eligibility
65 Years and older
Enrollment
250 participants
Timeline
2023 – 2027
U.S. locations
10
States / cities
Glendale, California • Mountain View, California • Carmel, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 24, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa

NCT00661479
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant, 100 µg Brimonidine Tartrate Implant, Sham (no implant)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 24, 2026, 2:34 PM EDT
Completed No phase listed Observational

Telemedicine Retinal Screening Utilizing a Mobile Medical Unit

NCT01412905
View directory record Official record
Conditions
Diabetes, Retinopathy
Interventions
Not listed
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
16 Years to 80 Years
Enrollment
1,229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 24, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration

NCT00766337
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Sirolimus in combination with ranibizumab, Placebo in combination with ranibizumab
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 24, 2026, 2:34 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia

NCT05620901
View directory record Official record
Conditions
Vitreoretinopathy, Coats' Disease, Exudative Retinopathy, Lattice Degeneration, Retinal Hole, Sickler's Syndrome, Retinal Detachment Rhegmatogenous, Retinal Detachment Exudative, Retinal Detachment Traction
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Pred Forte
Drug
Lead sponsor
Lejla Vajzovic, MD, FASRS
Other
Eligibility
3 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 24, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration

NCT00001615
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Corticosteroid
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 2:34 PM EDT
Completed No phase listed Observational

Efficacy of Elevated CD4 Counts on CMV Retinitis

NCT00091884
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 2:34 PM EDT
Completed Not applicable Interventional Results available

Use of Ocular Point of Care Ultrasound in Diagnosing Retinal Detachment in the Emergency Department

NCT03106025
View directory record Official record
Conditions
Retinal Detachment
Interventions
Ultrasound, Ophthalmology Assessment
Device · Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 24, 2026, 2:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease

NCT01937221
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild to Moderate Cognitive Impairment
Interventions
spectral-domain optical coherence tomography (SD-OCT)
Other
Lead sponsor
Duke University
Other
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 24, 2026, 2:34 PM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

NCT06132035
View directory record Official record
Conditions
Age-related Wet Macular Degeneration
Interventions
CG-P5 peptide, Placebo, Aflibercept Injection [Eylea]
Drug
Lead sponsor
Caregen Co. Ltd.
Industry
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Manchester, Connecticut • Deerfield Beach, Florida • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 24, 2026, 2:34 PM EDT
Completed Phase 3 Interventional

Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation

NCT00105404
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema, DME
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 2:34 PM EDT
Terminated Phase 1 Interventional

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

NCT03790852
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
KSI-301
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
21 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 24, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Gene Therapy for Gyrate Atrophy

NCT00001735
View directory record Official record
Conditions
Gyrate Atrophy
Interventions
Gene therapy
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 2:34 PM EDT
Enrolling by invitation Phase 1 Interventional

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

NCT05650749
View directory record Official record
Conditions
Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma, Retinoblastoma, Metastatic Retinoblastoma
Interventions
GPC2 CAR T cells
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
1 Year and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 24, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa

NCT04925687
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Intravitreal autologous CD34+ cells
Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 24, 2026, 2:34 PM EDT
Completed No phase listed Observational

Clinical Evaluation of the RAVI-Guide

NCT02196584
View directory record Official record
Conditions
Retinal Diseases
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 24, 2026, 2:34 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessment of AI Program 'DRISTi' as a Screening Tool

NCT07222293
View directory record Official record
Conditions
Diabetic Retinopathy (DR)
Interventions
Fundus Image Grading
Diagnostic Test
Lead sponsor
Artelus AI
Industry
Eligibility
21 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Oxford, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 24, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

ADVM-022 Intravitreal Gene Therapy for Wet AMD

NCT03748784
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
ADVM-022
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Bakersfield, California • Beverly Hills, California • Golden, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 24, 2026, 2:34 PM EDT
Not listed No phase listed Observational

Eye Movement Rehabilitation in Low Vision Patients

NCT04929756
View directory record Official record
Conditions
Low Vision, Age Related Macular Degeneration
Interventions
Visual Feedback
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
14 Years to 99 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 24, 2026, 2:34 PM EDT
Recruiting Not applicable Interventional

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease

NCT06380075
View directory record Official record
Conditions
Retinal Disease
Interventions
Spectralis FAF imaging, Optos imaging, Clarus imaging
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional Results available

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

NCT04684394
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration, Macular Degeneration
Interventions
GEM103, Aflibercept, Sham
Biological · Drug
Lead sponsor
Gemini Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
23
States / cities
Phoenix, Arizona • Campbell, California • Encino, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 24, 2026, 2:34 PM EDT